What REDEFINE 5 signals for obesity trials in Asia and beyond

The prevalence of obesity is rising worldwide, and Asia is not exempt from this epidemic. Epidemiological evidence consistently shows that, for a given BMI, many Asian populations have higher cardiometabolic risk than other racial groups.1 Accordingly, numerous Asian countries have adopted lower BMI thresholds (23–25 kg/m2) to define obesity based on their local epidemiological evidence.2–4 This is particularly important because cardiovascular disease remains the leading cause of death among people living with obesity,5 and the therapeutic landscape is rapidly evolving, particularly with nutrient-stimulated hormone therapies delivering clinically meaningful reductions in adiposity, key cardiometabolic risk factors, and even hard outcomes such as major adverse cardiovascular events.